Esperion(US:ESPR)2025-11-06 12:32Financial Performance - Q3 2025 total revenue increased by 69% year-over-year to $87.3 million, while U.S. net product revenue grew by 31% year-over-year to $40.7 million[1][11] - Total revenues for the three months ended September 30, 2025, were $87.3 million, a 69% increase from $51.6 million in the same period of 2024[32] - Product sales for the nine months ended September 30, 2025, reached $115.8 million, compared to $84.2 million in 2024, reflecting a 37.6% year-over-year growth[32] - Collaboration revenue for Q3 2025 was $46.7 million, a 128% increase compared to $20.5 million in Q3 2024[11] - Collaboration revenue for the three months ended September 30, 2025, was $46.7 million, significantly up from $20.5 million in the same period of 2024, marking a 127% increase[32] - Operating expenses for the three months ended September 30, 2025, totaled $97.3 million, compared to $67.7 million in 2024, representing a 43.8% increase[32] - The net loss for the three months ended September 30, 2025, was $31.3 million, slightly higher than the net loss of $29.5 million in the same period of 2024[32] - Cash and cash equivalents as of September 30, 2025, were $92.4 million, down from $144.8 million at the end of 2024[30] - The accumulated deficit as of September 30, 2025, was $1.69 billion, compared to $1.60 billion at the end of 2024[30] - The company reported a total stockholders' deficit of $451.4 million as of September 30, 2025, compared to $388.7 million at the end of 2024[30] Market Position and Product Development - Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines, which is expected to enhance its market position[4][6] - Over 90% of commercial lives and more than 80% of Medicare beneficiaries are now covered for NEXLETOL and NEXLIZET, reflecting improved payer access[6][3] - Total retail prescription equivalents increased by approximately 9%, with over 30,000 healthcare practitioners prescribing NEXLETOL and NEXLIZET in Q3 2025[6][3] - Royalty revenue from European sales increased by 21% sequentially to $16.4 million, indicating strong market growth for NILEMDO and NUSTENDI[6][11] - The company is advancing the development of ESP-2001 for primary sclerosing cholangitis, representing a potential market opportunity exceeding $1 billion annually[10] - Esperion is focused on developing ATP citrate lyase inhibitors (ACLYi) to enhance its product pipeline and market position[25] Research and Development - Research and development expenses for Q3 2025 were $14.1 million, a 36% increase from $10.4 million in Q3 2024, primarily due to ongoing clinical studies[11] - Esperion's ongoing CLEAR Cardiovascular Outcomes Trial involved nearly 14,000 patients, supporting the efficacy of its FDA-approved medications[24] Legal and Regulatory - The company reached settlement agreements with four ANDA filers, including Dr. Reddy's Laboratories, preventing the marketing of generic versions of bempedoic acid until April 2040[5][3] Future Outlook - The company expects full-year 2025 operating expenses to be in the range of $215 million to $235 million, with sustainable profitability anticipated starting in Q1 2026[13]